Ping An Insurance Group's technology arm, Ping An Technology, has completed a prospective multi-centre clinical trial for the world's first intelligent optical coherence tomography (OCT) retinal disease screening system. This development comes amidst Ping An's constant advancements in leveraging AI and its strong medical repository to establish a healthcare ecosystem.
The technology arm of Ping An Insurance Group has completed clinical trials for its retinal disease screening system. In a press release on Tuesday, the company said it had successfully tested the system in patients with macular degeneration (AMD), which is caused by damage to one or more layers of cells that are responsible